Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05792462
PHASE1/PHASE2

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

Sponsor: Tianjin Medical University General Hospital

View on ClinicalTrials.gov

Summary

Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation and differentiation. Baricitinib may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clinical trials may be needed to observe its efficacy and safety.

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2023-04-15

Completion Date

2025-12-30

Last Updated

2024-10-16

Healthy Volunteers

No

Interventions

DRUG

Baricitinib

Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.

Locations (1)

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China